NASDAQ: ALKS · Life Sciences · 7 alerts · CIK 1520262
Share price
$46.53Close, Nov 16
Market cap
$7.82B
Shares outstanding
168.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alkermes plc. filings on SEC EDGAR ↗
Alkermes entered into a settlement and license agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit regarding LYBALVI. Under the agreement, Teva is granted a non-exclusive, royalty-free license to market its generic version of the drug in the U.S. starting in November 2039, or May 2040 if pediatric exclusivity is obtained.
Alkermes EVP, CLO, Alkermes, Inc. David Joseph Gaffin Sells $94K of Stock
David Joseph Gaffin, EVP, CLO, Alkermes, Inc., sold 2,035 shares of Alkermes plc. at $46.17 a share, worth $94K in total on Nov 3, 2026. Shares held after the trade: 219,353 (-0.9%).
Alkermes plc reported a significant increase in cash and cash equivalents to $631.3 million as of September 30, 2026, compared to $388.6 million at year-end 2025. The company's intangible assets grew substantially from $0.8 million to over $1.74 billion, reflecting the impact of the Avadel Acquisition and its expanded neuroscience portfolio including LUMRYZ.
Alkermes plc reported third quarter 2026 total revenues of $480.1 million, driven by solid performance in its proprietary product portfolio including VIVITROL and LUMRYZ. The company reported GAAP net income of $16.3 million and reaffirmed its full-year 2026 financial expectations while highlighting progress in its orexin development programs.
Term
3 months
“We delivered solid commercial and financial performance in the third quarter while continuing to advance our portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions.”
Blair Jackson, President and Chief Executive Officer